NASDAQ:MRTX - Mirati Therapeutics Stock Price, Forecast & News

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Mirati Therapeutics Inc (NASDAQ:MRTX) posted its quarterly earnings results on Monday, November, 4th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.25) by $0.13. The biotechnology company earned $0.99 million during the quarter, compared to analyst estimates of $0.50 million. Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. View Mirati Therapeutics' Earnings History.

Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Mirati Therapeutics.

16 analysts have issued 12-month price targets for Mirati Therapeutics' shares. Their forecasts range from $81.00 to $130.00. On average, they expect Mirati Therapeutics' stock price to reach $107.21 in the next year. This suggests a possible upside of 10.6% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics.

News coverage about MRTX stock has been trending extremely negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Mirati Therapeutics earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Mirati Therapeutics.

Mirati Therapeutics saw a drop in short interest in December. As of December 13th, there was short interest totalling 4,410,000 shares, a drop of 9.4% from the November 28th total of 4,870,000 shares. Based on an average trading volume of 676,400 shares, the days-to-cover ratio is currently 6.5 days. Currently, 11.4% of the company's stock are sold short. View Mirati Therapeutics' Current Options Chain.

Some companies that are related to Mirati Therapeutics include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and Horizon Therapeutics (HZNP).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include AbbVie (ABBV), Arrowhead Pharmaceuticals (ARWR), Micron Technology (MU), Netflix (NFLX), NVIDIA (NVDA), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Advanced Micro Devices (AMD), Amarin (AMRN) and Exelixis (EXEL).

Mirati Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.32%), Tocqueville Asset Management L.P. (0.01%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Mirati Therapeutics stock include Aaron I Davis, Avoro Capital Advisors Llc, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Christopher C Lemasters, Craig A Johnson, Jamie A Donadio, Jamie Christensen, Michael G Grey and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics.

MRTX stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Tocqueville Asset Management L.P. and Nisa Investment Advisors LLC. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics.

Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MRTX stock can currently be purchased for approximately $96.97.

Mirati Therapeutics has a market capitalization of $3.82 billion and generates $12.93 million in revenue each year. The biotechnology company earns $-98,420,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Mirati Therapeutics employs 63 workers across the globe.View Additional Information About Mirati Therapeutics.

The official website for Mirati Therapeutics is http://www.mirati.com/.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected]